Biocon’s arm extends partnership with Bristol-Myers Squibb till 2026

14 Nov 2017 Evaluate

Biocon’s contract research arm -- Syngene International -- has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026. The expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations.

As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively for Bristol-Myers Squibb.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

381.35 -11.45 (-2.91%)
08-Dec-2025 15:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 924.35
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×